Lincoln Pharmaceuticals
Lincoln Pharmaceuticals Share Price Chart
Lincoln Pharmaceuticals last traded at ₹544.45 (2026-10-13). Over the past month the stock moved -14.5%, three months the stock moved -26.9%, year the stock moved -1.7%. Its closing range over 52 weeks is ₹453.20 – ₹745.25, with the latest close 26.9% below the high.
Closing prices up to 2026-10-13.
About Lincoln Pharmaceuticals
Incorporated in 1979, Lincoln Pharmaceuticals Ltd is in the business of manufacturing and trading of pharmaceutical products [1]
Product Portfolio:[1] The company has 1,700 registered products and 700 additional products in the pipeline. It has developed 600+ formulations across 15 therapeutic areas.
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Lincoln Pharmaceuticals reported sales of ₹177.00 crore (+14.9%) and net profit of ₹36.00 crore (+28.6%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 177.00 | 27.00 | 15.00 | 36.00 | 18.09 |
| Mar 2026 | 187.00 | 25.00 | 13.00 | 12.00 | 5.81 |
| Dec 2025 | 166.00 | 24.00 | 14.00 | 29.00 | 14.28 |
| Sep 2025 | 163.00 | 25.00 | 16.00 | 20.00 | 9.98 |
| Jun 2025 | 154.00 | 24.00 | 15.00 | 28.00 | 13.82 |
| Mar 2025 | 168.00 | 27.00 | 16.00 | 12.00 | 5.78 |
| Dec 2024 | 147.00 | 24.00 | 16.00 | 21.00 | 10.37 |
| Sep 2024 | 161.00 | 28.00 | 18.00 | 26.00 | 13.15 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +3.2% | +0.7% | +18.3% | +4.8% | +1.2% | +12.9% | +11.3% | +14.9% |
| Operating profit growth | -9.7% | -20.0% | +50.0% | +4.3% | -10.7% | +0.0% | -7.4% | +12.5% |
| Net profit growth | -7.1% | -25.0% | -36.8% | +16.7% | -23.1% | +38.1% | +0.0% | +28.6% |
| EPS growth | -4.7% | -25.9% | -37.8% | +16.9% | -24.1% | +37.7% | +0.5% | +30.9% |
| OPM % | 18.0% | 16.0% | 16.0% | 15.0% | 16.0% | 14.0% | 13.0% | 15.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Lincoln Pharmaceuticals reported sales of ₹671.00 crore (+7.7%) and net profit of ₹88.00 crore (+7.3%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 671.00 | 98.00 | 15.00 | 88.00 | 43.88 |
| Mar 2025 | 623.00 | 101.00 | 16.00 | 82.00 | 41.11 |
| Mar 2024 | 581.00 | 100.00 | 17.00 | 93.00 | 46.58 |
| Mar 2023 | 510.00 | 90.00 | 18.00 | 73.00 | 36.40 |
| Mar 2022 | 472.00 | 96.00 | 20.00 | 69.00 | 34.63 |
| Mar 2021 | 424.00 | 87.00 | 21.00 | 62.00 | 31.12 |
| Mar 2020 | 386.00 | 66.00 | 17.00 | 51.00 | 25.72 |
| Mar 2019 | 366.00 | 68.00 | 18.00 | 49.00 | 24.36 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +1.4% | +5.5% | +9.8% | +11.3% | +8.1% | +13.9% | +7.2% | +7.7% |
| Operating profit growth | +28.3% | -2.9% | +31.8% | +10.3% | -6.3% | +11.1% | +1.0% | -3.0% |
| Net profit growth | +40.0% | +4.1% | +21.6% | +11.3% | +5.8% | +27.4% | -11.8% | +7.3% |
| EPS growth | +40.7% | +5.6% | +21.0% | +11.3% | +5.1% | +28.0% | -11.7% | +6.7% |
| OPM % | 18.0% | 17.0% | 21.0% | 20.0% | 18.0% | 17.0% | 16.0% | 15.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Lincoln Pharmaceuticals.
Get Free AI Stock Analysis FREE →Latest News
-
Lincoln Pharmaceuticals proposes ₹1.80 per share final dividend for FY26 - scanx.trade
-
Lincoln Pharmaceuticals consolidated net profit rises 30.89% in the June 2026 quarter - business-standard.com
-
Lincoln Pharmaceuticals consolidated net profit rises 30.89% in the June 2026 quarter - Business Standard
-
Lincoln Pharmaceuticals Issues Public Notice for Transfer of Equity Shares to IEPF Authority - scanx.trade
-
Iran attacks USS Abraham Lincoln – But why Iran’s weapons cannot damage it
Frequently Asked Questions
What is Lincoln Pharmaceuticals's current stock price?
Lincoln Pharmaceuticals shares were last quoted at ₹544.45 (-2.5% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Lincoln Pharmaceuticals?
Lincoln Pharmaceuticals has a price-to-earnings (P/E) ratio of 12.26 and a price-to-book (P/B) ratio of 1.49. The industry P/E is 53.33.
What is the 52-week high and low of Lincoln Pharmaceuticals?
The 52-week high of Lincoln Pharmaceuticals is ₹770.00 and the 52-week low is ₹439.95.
What is the market cap of Lincoln Pharmaceuticals?
The market capitalisation of Lincoln Pharmaceuticals is about ₹1,182.56 crore.
How did Lincoln Pharmaceuticals perform in its latest quarterly results?
In the latest quarter (Jun 2026), Lincoln Pharmaceuticals reported sales of ₹177.00 crore (+14.9%) and net profit of ₹36.00 crore (+28.6%), compared with the same quarter last year.
Is Lincoln Pharmaceuticals a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Lincoln Pharmaceuticals has a 3-year ROE of 14.00%, 3-year profit growth of 7.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Lincoln Pharmaceuticals?
Promoters hold about 49.78% of Lincoln Pharmaceuticals.
Which sector does Lincoln Pharmaceuticals belong to?
Lincoln Pharmaceuticals belongs to the Pharmaceuticals & Drugs sector.